We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness


Novopharm Limited v. Eli Lilly and Company (2010 FC 915)
  • Gowling WLG
  • Canada
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection


Eli Lilly Canada inc. v. Apotex Inc. (2010 FC 952)
  • Gowling WLG
  • Canada
  • October 27 2010

Apotex brought a motion to set aside an Order from 2007 granting Eli Lilly’s applications for a prohibition Order in PMNOC proceedings


Be warned: online forum selection clauses may oblige you to litigate abroad
  • Gowling WLG
  • Canada
  • June 30 2015

The decision in Douez v. Facebook, Inc., provides some comfort to online businesses that rely upon forum selection clauses in their online contracts


Impacts of the Amazon.com decisions on medical use claims in Canada
  • Gowling WLG
  • Canada
  • July 13 2012

Methods of medical treatment and surgery are not statutory subject matter in Canada


Purdue Pharma v Minister of Health, judicial review of decision of Office of Patented Medicines and Lliaison (“OPML”), TARGIN, July 8, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Purdue filed a New Drug Submission ("NDS") as part of its application for a notice of compliance ("NOC") to market and sell the drug TARGIN in Canada


Novo Nordisk v. Cobalt Pharmaceuticals, S. 55.2 proceeding, Repaglinide, Aug. 3, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Cobalt served a NOA with respect to repaglinide, the S enantiomer of a previously disclosed racemic compound (the “388 compound”), alleging invalidity of the '851 patent on grounds of anticipation, obviousness and s. 53(1


Cojocaru v. British Columbia Women’s Hospital: Trial judges must show independent thought or risk being over turned
  • Gowling WLG
  • Canada
  • June 8 2011

The British Columbia Court of Appeal rejected a trial decision because the decision below did not appear to be the result of independent and impartial analysis: In Cojocaru (Guardian Ad Litem) v. British Columbia Women’s Hospital and Health Center (2011 BCCA 192), a majority of the British Columbia Court of Appeal ordered a new trial where the judgment of the trial judge consisted of an excessive verbatim re-counting of the successful party’s written submissions


Novopharm v Pfizer, motion for interim relief pending appeal, pregabalin, October 5, 2010
  • Gowling WLG
  • Canada
  • November 24 2010

See the earlier decisions in this case in the May 2010 and July 2010 editions of this newsletter


Merck-Frosst-Schering Pharma GP v. Canada (Health) (2010 FC 933)
  • Gowling WLG
  • Canada
  • October 27 2010

Merck-Frosst (“Merck”) applied for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for its generic version of Ezetimibe